Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365521 | 0.80 | MCHR1 (0.57) | MCHR1HRH3MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL2883772 | 0.78 | MCHR1 (0.56) | MCHR1HRH3 | |
| SCHEMBL1367169 | 0.78 | MCHR1 (0.65) | MCHR1HRH3MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL1364747 | 0.77 | MCHR1 (0.63) | MCHR1HRH3MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL1364816 | 0.76 | MCHR1 (0.82) | MCHR1HRH3 | |
| SCHEMBL6224972 | 0.76 | HSP90AB1 (0.51) | MCHR1HRH3MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL10205757 | 0.75 | MCHR1 (0.53) | MCHR1HRH3MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL1364977 | 0.73 | MCHR1 (0.51) | MCHR1HRH3MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL1367251 | 0.72 | MCHR1 (0.74) | MCHR1 | |
| SCHEMBL1365779 | 0.72 | MCHR1 (0.68) | MCHR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | MSD K.K. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1916239-A1 | PYRIDONE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | NPY1R, MC5R, MC1R | MCHR1 4/4885HRH3 208/4885MBTD1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.